Skip to main content

Advertisement

SpringerLink
Log in

Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

We investigated the ophthalmologic manifestations and factors that influence outcomes in patients with myasthenia gravis (MG). We retrospectively analyzed the prevalence of neuro-ophthalmologic findings and clinical and outcome measures of 100 consecutive patients (53 males, 47 females), aged 55.7 ± 17.5 (range 15–85) years with an established diagnosis of MG. Forty-eight patients had purely ocular symptoms at the onset of disease (OMG) and 52 patients presented with generalized symptoms (GMG). Overall, 21 patients presented with extraocular muscle (EOM) weakness. Bilateral EOM weakness was seen in 12 patients, and unilateral EOM weakness was seen in nine patients. Diplopia responded partially to immunosuppressive treatments in 60% of patients with ophthalmoparesis. Twenty-five (52.1%) patients with ocular-onset MG converted to secondary GMG at a mean time of 14.5 months. Patients who developed secondary GMG were younger and had an earlier age of disease onset when compared with patients with pure OMG (p < 0.05). Patients with secondary GMG presented more frequently with ptosis and diplopia (72% vs. 28%) compared with patients with pure ocular MG who presented more frequently with isolated ptosis (66.7% vs. 33.3%) (p = 0.02). Remission and minimal manifestation status were achieved in 50 (79.3%) of all patients with a clinical follow-up ≥ 3 years. Poor outcome was associated with the presence of thymoma (p < 0.05). Myasthenic ophthalmoparesis is bilateral and heterogeneous and partly responds to treatment with immunotherapy. Younger patients with ptosis and diplopia at disease onset had an increased risk of secondary GMG. The presence of thymoma increases the risk for poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3

    Article  CAS  PubMed  Google Scholar 

  2. Smith SV, Lee AG (2017) Update on ocular myasthenia gravis. Neurol Clin 35:115–123. https://doi.org/10.1016/j.ncl.2016.08.008

    Article  PubMed  Google Scholar 

  3. Benatar M, Sanders DB, Wolfe GI, McDermott MP, Tawil R (2012) Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275:17–22. https://doi.org/10.1111/j.1749-6632.2012.06780.x

    Article  CAS  PubMed  Google Scholar 

  4. Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122:1517–1521. https://doi.org/10.1016/j.ophtha.2015.03.010

    Article  PubMed  Google Scholar 

  5. Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756–760. https://doi.org/10.1002/mus.25983

    Article  CAS  PubMed  Google Scholar 

  6. Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 205:99–105. https://doi.org/10.1016/j.ajo.2019.04.017

    Article  PubMed  PubMed Central  Google Scholar 

  7. Li F, Hotter B, Swierzy M, Ismail M, Meisel A, Rückert JC (2018) Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265:2773–2782. https://doi.org/10.1007/s00415-018-9056-8

    Article  PubMed  Google Scholar 

  8. Bandini F, Faga D, Simonetti S (2001) Ocular myasthenia mimicking a one-and-a-half syndrome. J Neuroophthalmol 21:210–211. https://doi.org/10.1097/00041327-200109000-00010

    Article  CAS  PubMed  Google Scholar 

  9. Das JC, Chaudhuri Z, Bhomaj S, Sharma P, Aggarwal M (2002) Ocular myasthenia presenting as progressive external ophthalmoplegia. J Pediatr Ophthalmol Strabismus 39:52–54

    Article  Google Scholar 

  10. Kupersmith MJ, Ying G (2005) Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 89:1330–1334. https://doi.org/10.1136/bjo.2004.063404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Benatar M, Kaminski HJ, Quality Standards Subcommittee of the American Academy of Neurology (2007) Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68:2144–2149. https://doi.org/10.1212/01.wnl.0000263481.14289.90

    Article  Google Scholar 

  12. Argyriou AA, Karanasios P, Potsios C, Makridou A, Doukas V, Koukopoulou I, Makris N (2009) Myasthenia gravis initially presenting with pseudo-internuclear ophthalmoplegia. Neurol Sci 30:387–388. https://doi.org/10.1007/s10072-009-0106-y

    Article  PubMed  Google Scholar 

  13. Cleary M, Williams GJ, Metcalfe RA (2008) The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus 16:11–18. https://doi.org/10.1080/15569520701830992

    Article  PubMed  Google Scholar 

  14. Almog Y, Ben-David M, Nemet AY (2016) Inferior oblique muscle paresis as a sign of myasthenia gravis. J Clin Neurosci 25:50–53. https://doi.org/10.1016/j.jocn.2015.08.026

    Article  PubMed  Google Scholar 

  15. Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E (2017) Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry 88:761–763. https://doi.org/10.1136/jnnp-2017-315782

    Article  PubMed  Google Scholar 

  16. Al-Haidar M, Benatar M, Kaminski HJ (2018) Ocular Myasthenia. Neurol Clin 36:241–251. https://doi.org/10.1016/j.ncl.2018.01.003

    Article  PubMed  Google Scholar 

  17. Heckmann JM, Nel M (2018) A unique subphenotype of myasthenia gravis. Ann N Y Acad Sci 1412:14–20. https://doi.org/10.1111/nyas.13471

    Article  CAS  PubMed  Google Scholar 

  18. Europa TA, Nel M, Heckmann JM (2018) Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve 58:542–549. https://doi.org/10.1002/mus.26172

    Article  CAS  PubMed  Google Scholar 

  19. Stålberg E (2012) Jitter analysis with concentric needle electrodes. Ann N Y Acad Sci 1274:77–85. https://doi.org/10.1111/j.1749-6632.2012.06775.x

    Article  PubMed  Google Scholar 

  20. Sirin NG, Orhan EK, Durmus H, Oflazer P, Parman Y, Oge AE, Deymeer F, Baslo MB (2017) Jitter measurement using a concentric Needle in 133 patients with myasthenia gravis: a retrospective analysis. Neurol Sci Neurophysiol 34:207–214. https://doi.org/10.24165/jns.10168.17

    Article  Google Scholar 

  21. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23. https://doi.org/10.1212/wnl.55.1.16

    Article  Google Scholar 

  22. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419–425. https://doi.org/10.1212/WNL.0000000000002790

    Article  PubMed  PubMed Central  Google Scholar 

  23. Beekman R, Kuks JB, Oosterhuis HJ (1997) Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 244:112–118. https://doi.org/10.1007/s004150050059

    Article  CAS  PubMed  Google Scholar 

  24. Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J (2003) Childhood ocular myasthenia gravis. Ophthalmology 110:1458–1462. https://doi.org/10.1016/S0161-6420(03)00460-3

    Article  PubMed  Google Scholar 

  25. Oosterhuis HJ (1982) The ocular signs and symptoms of myasthenia gravis. Doc Ophthalmol 52:363–378

    Article  CAS  Google Scholar 

  26. Bennett DL, Mills KR, Riordan-Eva P, Barnes PR, Rose MR (2006) Anti-MuSK antibodies in a case of ocular myasthenia gravis. J Neurol Neurosurg Psychiatry 77:564–565. https://doi.org/10.1136/jnnp.2005.075812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Okamoto K, Ito J, Tokiguchi S, Furusawa T (1996) Atrophy of bilateral extraocular muscles. CT and clinical features of seven patients. J Neuroophthalmol 16:286–288

    Article  CAS  Google Scholar 

  28. Gratton SM, Herro A, Bermudez-Magner JA, Guy J (2014) Atrophy and fibrosis of extra-ocular muscles in anti-acetylcholine receptor antibody myasthenia gravis. Open J Ophthalmol 4:117. https://doi.org/10.4236/ojoph.2014.44019

    Article  Google Scholar 

  29. Rautenbach RM, Pillay K, Murray ADN, Heckmann JM (2017) Extraocular muscle findings in myasthenia gravis associated treatment-resistant ophthalmoplegia: a case report. J Neuroophthalmol 37:414–417. https://doi.org/10.1097/WNO.0000000000000534

    Article  PubMed  Google Scholar 

  30. Liu R, Xu H, Wang G, Li J, Gou L, Zhang L, Miao J, Li Z (2013) Extraocular muscle characteristics related to myasthenia gravis susceptibility. PLoS ONE 8:e55611. https://doi.org/10.1371/journal.pone.0055611

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nel M, Jalali Sefid Dashti M, Gamieldien J, Heckmann JM (2017) Exome sequencing identifies targets in the treatment-resistant ophthalmoplegic subphenotype of myasthenia gravis. Neuromuscul Disord 27:816–825. https://doi.org/10.1016/j.nmd.2017.06.009

    Article  PubMed  Google Scholar 

  32. Tateno F, Sakakibara R, Kishi M, Ogawa E (2011) Hashimoto’s ophthalmopathy. Am J Med Sci 342:83–85. https://doi.org/10.1097/MAJ.0b013e318219bcf6

    Article  PubMed  Google Scholar 

  33. Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41:379–384. https://doi.org/10.1002/mus.21555

    Article  PubMed  Google Scholar 

  34. Cortés-Vicente E, Álvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, Pardo J, Ramos-Fransi A, Sevilla T, López de Munain A, Gómez MT, Jericó I, Gutiérrez-Gutiérrez G, Pelayo-Negro AL, Martín MA, Mendoza MD, Morís G, Rojas-Garcia R, Díaz-Manera J, Querol L, Gallardo E, Vélez B, Albertí MA, Galán L, García-Sobrino T, Martínez-Piñeiro A, Lozano-Veintimilla A, Fernández-Torrón R, Cano-Abascal Á, Illa I (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94(11):e1171–e1180

    Article  Google Scholar 

  35. Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79:113–117. https://doi.org/10.1159/000487132

    Article  PubMed  Google Scholar 

  36. Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17(1):77. https://doi.org/10.1186/s12883-017-0857-7

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC; Korean Research Group for Neuromuscular Diseases (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273:10–14. https://doi.org/10.1016/j.jns.2008.05.023

    Article  Google Scholar 

  38. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217:131–133. https://doi.org/10.1016/j.jns.2003.08.017

    Article  CAS  PubMed  Google Scholar 

  39. Yildiz Celik S, Durmus H, Yilmaz V, Saruhan Direskeneli G, Gulsen Parman Y, Serdaroglu Oflazer P, Deymeer F (2020) Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurol Belg 120:133–140. https://doi.org/10.1007/s13760-019-01252-x

    Article  PubMed  Google Scholar 

  40. Romi F (2011) Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011:474512. https://doi.org/10.4061/2011/474512

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Neurology Department, Istanbul Okmeydani Training and Research Hospital, Istanbul, Turkey

    Onur Akan

  2. Neurology Department, Trakya University Hospital, Balkan Yerleskesi, 22130, Edirne, Turkey

    Leyla Baysal-Kirac

Authors
  1. Onur Akan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leyla Baysal-Kirac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leyla Baysal-Kirac.

Ethics declarations

Conflict of interest

The author(s) declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical statement

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akan, O., Baysal-Kirac, L. Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis. Acta Neurol Belg 121, 1131–1140 (2021). https://doi.org/10.1007/s13760-020-01556-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-020-01556-3

Keywords

Search

Navigation